Technology | 2021.09.02
Sentien Biotechnologies Partners with BARDA to Evaluate High Dose Cohort in Phase 1/2 Trial of SBI-101 for Treatment of Acute Kidney Injury Associated with Sepsis
Collaboration Under BARDA DRIVe Solving Sepsis Program to also Support Key Regulatory Path Activities to Advance Development of SBI-101
(PRWeb September 02, 2021)
For more information, please visit
https://www.prweb.com/releases/sentien_b[...]_with_sepsis/prweb18166631.htm
